Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

New Visiongain report Global antibacterial drugs market 2019 2029

3 views

Published on

This report also includes revenue forecasts for the 43 leading marketed antibacterial drugs from 2019-2029.
For full report, visit: Visiongain.com
Direct link: https://www.visiongain.com/report/global-antibacterial-drugs-market-2019-2029/

Published in: Business
  • Be the first to comment

  • Be the first to like this

New Visiongain report Global antibacterial drugs market 2019 2029

  1. 1. www.visiongain.com/industries/pharma Page 62 Global Antibacterial Drugs Market 2019-2029: Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems and Others 4. Cephalosporins Market Forecast 2019-2029 Cephalosporin drugs are among the most diverse classes of antibiotics, and are themselves sub- grouped into first, second, third, fourth, and the recent fifth generation drugs. Each generation has a broader spectrum of activity than its predecessor. The third-generation drugs, cefotaxime, ceftizoxime, ceftriaxone and some others can cross the blood-brain barrier (BBB) and may be used to treat meningitis and encephalitis. Fifth generation cephalosporins are beginning to reach the market now, with Teflaro and Zeftera the most recent market entrants. The next generation of cephalosporins are being developed in combination with β-lactamase inhibitors. Cephalosporin’s are the preferred agents for prophylactic treatment of surgical site infections. Cephalosporins are among the most commonly prescribed classes of antibiotics worldwide, reportedly leading in emerging markets and ranking second to penicillins in developed markets. The first cephalosporin was launched in the mid-1960s. There are now seven cephalosporin products identified in the market (Table 4.1). Table 4.1 Leading Branded Cephalosporin Antibacterial Drugs: Important Facts, 2018 Drug Company First Approval First Patent Expiry Administration Route Rocephin (ceftriaxone) Roche 1986 2002 IV, IM Zinnat/Ceftin (cefuroxime) GSK 1987 2003 Oral Flomox (cefcapene pivoxil) Shionogi 1997 2010 Oral Sulperazon (cefoperazone/sulbactam) Pfizer 1982 - IV, IM Meiact (cefditoren pivoxil) Vansen Pharma / Meiji Seika Pharma 1994 2016 Oral Teflaro / Zinforo (ceftaroline fosamil) Forest Labs / AstraZeneca 2011 2018 IV Zeftera (ceftobiprole) Basilea Pharmaceutica 2013 2023 IV 4.1 Cephalosporins Market 2018 – No Dominant Brands In 2018, the cephalosporin submarket was the largest sector of the antibacterial drugs market, accounting for 27.5% of the global antibacterial drug market at revenue of $11.78bn. The three highest earing brands are in this class are Pfizer’s Sulperazon, Takeda’s Teflaro and Roche’s Rocephin. In 2018, these drugs achieved revenues of $0.29bn, $0.53bn and $0.29bn and accounting for 2.5%, 4.5% and 2.5% of the submarket respectively (Table 4.2 and Figure 4.1). Source: Visiongain 2019, Drugs.com
  2. 2. www.visiongain.com/industries/pharma Page 228 Global Antibacterial Drugs Market 2019-2029: Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems and Others Table 11.18 Spanish Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2019-2029 Figure 11.12 Spanish Antibacterial Drugs Market: Revenue Forecast ($bn), 2019-2029 11.8 Japan – Still the Fourth Largest National Market In terms of antibacterial drug revenues, Japan is the world’s fourth largest market. In 2018, revenues for antibacterial drugs there totalled $3.54bn. Many leading antibacterial drugs are marketed there by domestic manufacturers. A number of the world’s leading antibiotics were also developed in that country, including meropenem (marketed worldwide as Merrem by AstraZeneca and in Japan as Meropen by Dainippon Sumitomo) and levofloxacin (marketed as Levaquin worldwide by J&J and as Cravit in Japan by Daiichi Sankyo). As well as these globally available products, a number of antibacterial drugs are available in the Japanese - or Asian - market only. 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 Spain 0.76 0.76 0.76 0.78 0.80 0.81 0.83 0.85 0.87 0.89 0.91 0.93 Annual Growth (%) 0.0% 0.0% 2.6% 2.6% 1.3% 2.5% 2.4% 2.4% 2.3% 2.2% 2.2% CAGR (2019-2023) CAGR (2019-2029) 1.6% CAGR (2024-2029) 2.3% 2.0% 0.00 0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 0.90 1.00 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 Revenue($bn) Year Source: Visiongain 2019 Source: Visiongain 2019. CAGR for period 2019-2023, 2024-2029, and 2019-2029
  3. 3. www.visiongain.com/industries/pharma Page 253 Global Antibacterial Drugs Market 2019-2029: Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems and Others 12.7.3 Key Developments Table 12.14 Allecra Therapeutics GmbH: Developments Date Type Description February, 2018 Designation Allecra Therapeutics announced that the U.S Food and Drug Administration (FDA) granted Fast Track designation for the company’s lead product candidate AAI101 when given in fixed dose combination with the antibiotic cefepime, a powerful treatment for serious hospital-acquired Infections 12.8 Adenium Biotech ApS 12.8.1 Overview Founded in 2011 and headquartered at Denmark, Adenium Biotech ApS, spun out from Novozymes A/S in 2011, is a clinical stage biopharmaceutical company which engages in the development and commercialization of antibiotics for the treatment of gram-negative bacterial infections. The company specializes in solutions for the treatment of hospital-acquired infections, such as complicated urinary tract infections and hospital acquired pneumonia caused by multi-resistant gram-negative bacteria. 12.8.2 Pipeline Portfolio Table 12.15 Adenium Biotech ApS: Pipeline Portfolio Product Indication Phase AA139 AA139 AP138 MDR cUTI MDR G neg Pneumonia MRSA Implant Infection Phase I Phase I Phase I Source: Visiongain 2019 Source: Visiongain 2019

×